Chimerix Inc (CMRX) Expected to Announce Quarterly Sales of $970,000.00
Wall Street brokerages forecast that Chimerix Inc (NASDAQ:CMRX) will announce sales of $970,000.00 for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Chimerix’s earnings, with estimates ranging from $500,000.00 to $1.20 million. Chimerix posted sales of $900,000.00 in the same quarter last year, which suggests a positive year over year growth rate of 7.8%. The business is expected to report its next earnings results on Wednesday, November 14th.
On average, analysts expect that Chimerix will report full-year sales of $3.63 million for the current financial year, with estimates ranging from $1.98 million to $4.81 million. For the next financial year, analysts expect that the firm will post sales of $5.85 million per share, with estimates ranging from $3.80 million to $11.00 million. Zacks’ sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Chimerix.
Chimerix (NASDAQ:CMRX) last released its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.05. The company had revenue of $1.19 million during the quarter, compared to analysts’ expectations of $0.94 million. Chimerix had a negative net margin of 1,582.64% and a negative return on equity of 34.94%.
Chimerix stock traded up $0.01 during trading hours on Friday, hitting $3.72. The company had a trading volume of 618 shares, compared to its average volume of 144,229. The stock has a market cap of $179.14 million, a price-to-earnings ratio of -2.46 and a beta of 1.08. Chimerix has a 1 year low of $3.57 and a 1 year high of $5.94.
Large investors have recently bought and sold shares of the company. Quantitative Systematic Strategies LLC bought a new stake in shares of Chimerix in the 1st quarter valued at about $115,000. MetLife Investment Advisors LLC bought a new stake in shares of Chimerix in the 1st quarter valued at about $127,000. Wells Fargo & Company MN raised its holdings in shares of Chimerix by 46.1% in the 1st quarter. Wells Fargo & Company MN now owns 33,569 shares of the biopharmaceutical company’s stock valued at $175,000 after purchasing an additional 10,598 shares in the last quarter. A.R.T. Advisors LLC bought a new stake in shares of Chimerix in the 1st quarter valued at about $252,000. Finally, Alps Advisors Inc. raised its stake in shares of Chimerix by 21.0% during the 1st quarter. Alps Advisors Inc. now owns 63,099 shares of the biopharmaceutical company’s stock worth $328,000 after acquiring an additional 10,967 shares in the last quarter. Institutional investors and hedge funds own 72.98% of the company’s stock.
Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.
Featured Article: Intrinsic Value
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.